Clinical trials: Delusional Disorder
Schizophrenia, Schizophreniform Disorders
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses.
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00419146
- Testing
- Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C
- Where
- Norway
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University Hospital, Aker
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Major Depressive Disorder With Psychotic Features
Study of Pharmacotherapy of Psychotic Depression
This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
- Trial name
- STOP-PD (NCT00056472)
- Testing
- Olanzapine, Sertraline
- Where
- 4 sites in United States, Canada
- Volunteers
- 259 people
- Sponsor
- Weill Medical College of Cornell University
Delusions, Schizophrenia
Metacognitive Training in Schizophrenia
Over a period of 4 weeks, metacognitive training for schizophrenia patients (MCT), delivered both in a group and individually, is compared to cognitive remediation (CogPack training).
- Trial name
- MCT (NCT01029067)
- Testing
- Metacognitive training, Cognitive Remediation
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or…
- Conditions
- Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder
- Trial name
- Ra-P-OCD (NCT04323566)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Uppsala University Hospital
Schizophrenia, Delusional Disorders (ICD-10)
Cognitive Determinants of Psychoeducation and Information in Psychoses
The aim of the study is to examine whether the efficacy of psychoeducation in patients with schizophrenia or schizoaffective disorders is dependent on their cognitive performance level and if a preceding cognitive training can…
- Trial name
- COGPIP (NCT00646256)
- Testing
- COGPACK training, psychoeducation
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- German Research Foundation
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia, Schizoaffective Disorder
Shared Decision Making for Antipsychotic Medications
This study aims to provide an evidence-based shared decision making intervention for antipsychotic medications, the Antipsychotic Medication Decision Aid (APM-DA), for individuals experiencing early psychosis and provide, for the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05416658
- Testing
- The Antipsychotic Medication Decision Aid (APM-DA)
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Paranoid Schizophrenia, Schizophrenia and Related Disorders
Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for "Paranoia".
The study is a randomised, assessor-blinded parallel-groups superiority clinical trial fulfilling the CONSORT criteria for non-pharmacological treatment.
- Conditions
- Paranoid Schizophrenia, Schizophrenia and Related Disorders, Schizophrenia Prodromal, Schizotypal Disorder
- Trial name
- FYF (NCT04902066)
- Testing
- Cognitive Behavioural Virtual Reality Therapy., Traditional Cognitive Behavioural Therapy
- Where
- Denmark
- Volunteers
- 259 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Psychosis
Effects of Online Metacognitive Training Group on Distressing Beliefs
Psychosis is characterized by distorted perceptions of reality, often involving persecutory delusions. Research links these symptoms to cognitive biases like "jumping to conclusions." Despite mixed reviews of Cognitive Behavioral…
- Trial name
- NCT06703827
- Testing
- The metacognitive training group
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- City, University of London
Paranoia in People With Schizophrenia-spectrum Diagnosis
Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial
People with a schizophrenia spectrum diagnosis often experience distressing worries or beliefs about others intending to cause them harm (also known as paranoia).
- Trial name
- CITADEL (NCT01920685)
- Testing
- Anxiety intervention
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- King's College London
Schizoaffective Disorder, Schizophrenia
Genetic Study of Schizophrenia
This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.
- Trial name
- NCT00001486
- Where
- United States
- Volunteers
- 4,914 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
SUCCEED Africa: Support, Comprehensive Care and Empowerment of People With Psychosocial Disabilities
Although psychotic disorders typically affect less than 1% of the population, they are a significant cause of disability worldwide.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizotypal Disorder, Acute and Transient Psychotic Disorder
- Trial name
- SUCCEED (NCT06007105)
- Testing
- SUCCEED Community-Based Intervention
- Where
- 4 sites in Malawi, Nigeria and 2 more
- Volunteers
- 425 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Psychosis Associated With Alzheimer's Disease
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie…
- Trial name
- NCT07459660
- Testing
- ML-007C-MA
- Where
- 8 sites in United States, Bulgaria and 1 more
- Volunteers
- 210 people
- Sponsor
- MapLight Therapeutics
Schizophrenia, Psychotic Disorders
Efficacy and Mechanisms of Change of an Emotion-oriented Version of Cognitive-behavioral Therapy for Psychosis
The aim of the present single-blind randomized-controlled therapy study is to assess the efficacy of a new form of Cognitive Behavioral Therapy for delusions with a focus on emotion regulation, improvement of self-esteem and…
- Conditions
- Schizophrenia, Psychotic Disorders, Delusions, Emotions
- Trial name
- CBTd-E (NCT02787135)
- Testing
- emotion-oriented Cognitive Behavior Therapy
- Where
- 2 sites in Germany
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Philipps University Marburg
Paranoia, Persecutory Delusion
Recovery From Paranoia: a Qualitative Exploration
Paranoia, the experience of undue or excessive mistrust, exists on a continuum which includes suspicious thoughts, ideas of reference, and persecutory delusions.
- Trial name
- NCT04824781
- Testing
- Qualitative interview
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- University of Oxford
Schizophrenia, Schizoaffective Disorder
D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
This study is a placebo-controlled 12 week trial of DCS augmentation of once-weekly CBT sessions in 60 schizophrenia subjects with antipsychotic-resistant delusions.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT01981759
- Testing
- D-Cycloserine, Cognitive Behavioral Therapy
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- NYU Langone Health
Alzheimer's Disease
CATIE-Alzheimer's Disease Trial
The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or…
- Trial name
- NCT00015548
- Testing
- Olanzapine, Quetiapine, Risperidone
- Where
- 34 sites in United States
- Volunteers
- 450 people
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer's Disease Psychosis
ACP-204 in Adults With Alzheimer's Disease Psychosis
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP Substudy 1 (Phase 2) will evaluate efficacy and dose…
- Trial name
- NCT06159673
- Testing
- ACP-204
- Where
- 154 sites in United States, Brazil and 10 more
- Volunteers
- 1,074 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.